Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Niagen Bioscience, Inc.: Amended and restated bylaws to accommodate universal proxy rules, revise advance notice provisions, address DGCL changes, and make administrative changes (effective 2023-03-16).
- Change
- bylaw amendment
- Effective
- 2023-03-16
Exact text from the filing
On March 16, 2023, the Board of Directors (the “Board”) of ChromaDex Corporation (the “Company”) amended and restated the Amended and Restated Bylaws of the Company (as so amended and restated, the “Amended and Restated Bylaws”) in order to, among other things (i) revise and enhance certain provisions to accommodate the universal proxy rules adopted by the Securities and Exchange Commission (Rule 14a-19), (ii) revise the information and other requirements of the Company’s advance notice provisions for stockholder proposals and nominations, (iii) address changes in the Delaware General Corporations Law relating to the provision of a list of stockholders in connection with stockholder meetings and (iv) make certain administrative and clarifying changes.
View on SEC.gov